<aside> 🧬 “Biology is the next big thing. If I were young today, I would do biology” - Eric Schmidt.
</aside>
You don’t see your dream position? Our door is always open for enthusiastic talents who see how they can contribute to our mission. Drop an email at [email protected] and explain what you want to do with us!
<aside> 🧬 We are on a mission to transform drug development in oncology and we are seeking exceptional talents to join us.
</aside>
Developing new drugs in oncology is a massive challenge. Today, less than 5% of new cancer drugs make it through clinical trials and new molecules reach patients only after 10 years of research and billions invested in R&D. This leads to less drugs available to patients and at a steep cost for healthcare systems. At Orakl, our mission is to make revolutionary treatments available to the right patients, faster.
👉 To learn more about why we’re building Orakl, read here and head to our website.
Orakl Oncology is a techbio company, based in Paris and aiming to transform the fight against cancer. We are an interdisciplinary platform working at the intersection of cell biology, engineering and machine learning to enable companies to identify and optimise new anti-cancer therapies. Orakl Oncology is a spin-off from the Gustave Roussy Institute, our offices are located in Paris and our lab in le Kremlin-Bicêtre, France.
We have raised more than 6M€ private and public funding with exceptional investors such as SpeedInvest, Verve Ventures and HCVC, and individuals like Sébastien Bazin and Jonathan Benhamou. We’re also lucky to have been featured in Les Echos, Sifted, nominated by Unicancer as “best digital innovation” of 2023 and more recently “Grand Prix i-Lab” of France innovation competition.